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Amyloidosis encompasses a  group of diseases characterized by the  deposition of 
large amounts of certain types of extracellular fibrillar proteins in a variety of organs. 
Sections of the involved tissues reveal, in addition to the proteinaceous deposits, an 
infiltration of large pyroninophilic cells. Two types of amyloid occur most frequently. 
One  of these,  seen  in  patients  with  multiple  myeloma,  macroglobulinemia,  and 
primary  amyloidosis,  is  immunoglobulin-related  amyloid  which  has  as  its  major 
component fragments of light chains of varying size (1-3). The second is a  nonim- 
munoglobulin form (4-8) which develops in association with various chronic inflam- 
matory diseases  and  in  almost  all experimental models of amyloidosis  (9-11).  The 
major component of this type of amyloid fibril is the 8,500 dalton amyloid A  (AA) 1 
protein  (4-8).  In  addition  to  these two  types,  there exist  a  number of rare  forms 
including a  variety of familial types, senile amyloid deposits, (12), and the amyloid 
that is localized in the skin and in certain endocrine glands (13), all of which seem to 
be derived from a  precursor synthesized either locally or at a  distant site.  Whereas 
some information is available concerning the mechanism of degradation of L chains 
to L chain-related amyloid by proteolytic enzymes or tissue lysosomes (14-16), little 
is known about the origin of protein AA or the removal of amyloid deposits in the 
rare instances where recovery occurs. 
Normal serum  contains small  amounts of a  12,500-dalton  component known  as 
serum amyloid A  related protein  (SAA)  whose concentration increases several fold 
during many inflammatory and neoplastic states and returns to normal levels rapidly 
with recovery (17).  SAA has antigenic properties similar to protein AA and has an 
identical amino acid sequence for at least the first 55 residues (18-21). Because SAA 
differs from protein AA in having a carboxy terminal extension, it seems likely that 
this part is cleaved when the AA protein is formed. The absence of protein AA from 
blood suggests  that  cleavage occurs in  the  tissues where amyloid is  deposited.  We 
therefore initiated a series of studies to investigate the mechanisms of degradation of 
SAA and AA in the hope of providing insights into the pathogenesis of the disease 
and  into  the  causes  for  its  development  in  only a  fraction of subjects  exposed  to 
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prolonged  periods  of overproduction  of  SAA.  The  study  is  focused  on  the  blood 
monocytes which, together with the closely related tissue macrophages, play a  major 
role  in  the  elimination  of foreign  materials  through  a  process  of engulfment  and 
degradation within lysosomes (22)  and through the secretion of many proteases such 
as  collagenase  (23),  elastase  (24),  and  plasminogen  activators  (25,  26)  into  the 
extraeellular medium. Accordingly, we developed an in vitro system which shows that 
blood monocytes can degrade SAA to products very similar to protein AA and which 
enabled us to study the fate of the AA protein. This communication also presents the 
mechanism  by which such degradation occurs and the location of the enzymes that 
may be involved in the process. The results raise some interesting questions concerning 
mechanisms which may be operative in the pathogenesis of the various forms of the 
disease. 
Materials and  Methods 
Preparation of SAA.  SAA was purified from.the serum of a patient with macroglobulinemia 
and another one with an IgA myeloma. Serum was dialyzed against water, the supernate was 
made  10% in formic acid, and passed sequentially through Sephadex G-100, G-75, and G-50 
columns (Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, N. J.) as previously 
described (21). 
Preparation of Protein AA.  Protein AA was prepared from the liver of a patient with secondary 
amyioid by distilled water extraction followed by chromatography on Sephadex G-100 in 5 M 
guanidine, and  1 M  acetic acid (1, 27). 
Cells.  Peripheral blood monocytes from  the blood of 20 normal donors, 6  patients with 
primary  amyloidosis, and  4  patients  with  secondary  amyloidosis were  isolated  on  Ficoll- 
Hypaque (Pharmacia Fine Chemicals Inc.) and cultured as described elsewhere (28-30). Briefly, 
the cells were  plated in  100-mm  tissue culture dishes (BioQuest, BBL,  & Falcon Products, 
Cockeysville, Md.)  at  a  concentration  of  107  cells per plate  in  RPMI-1640  (Grand  Island 
Biological Co., Grand Island, N. Y.)  medium, supplemented with  15%  fetal calf serum, and 
incubated at 37°C in an atmosphere of 10% CO2, 90% air for a 24-h period. The culture dishes 
were washed with RPMI medium, refrigerated for 1 h, and the cells removed from the plates 
with a rubber policeman. The harvested cells consisted of 99% monocytes on morphologic and 
functional grounds (29, 30). 
Degradation of SAA and Protein AA ~y Cells.  The monocytes purified as described above were 
suspended at a  concentration of 10  cells/tube in  10-ml plastic test tubes containing 0.75 ml 
serum-free Dulbecco-s medium  (Grand Island Biological Co.) with penicillin-streptomycin to 
which SAA or protein AA was added at a  final concentration of 500/zg/ml. Aliquots of the 
medium were collected after different periods of incubation, in most cases, 2,  24,  and 48  h, 
frozen, lyophilized, and examined on  10-20%  sodium dodecyl sulfate (SDS)-polyacrylamide 
gradient slab gels (31). Where quantitative data were required the stained gels were scanned at 
550  nm on a  Gilford 250 spectrophotometer (Gilford Instrument Laboratories Inc., Oberlin, 
Ohio) equipped with a scanner and recorder. 
Release of Enzymes by  Cells.  Degradative activity for  SAA in  the  supernates  of cultured 
monocytes, and  the effects of SAA and  aggregated gamma globulin on  the  release of such 
enzymes was assessed as follows: monocytes were incubated in serum-free Dulbecco's medium, 
or in medium containing either 50/zg/ml of SAA or 100 #g/ml of aggregated gamma globulin 
for 0.5  and  3  h.  After incubation,  the  cells were spun  down  at  300  g  for  5  rain,  and  the 
supernates were collected and incubated with SAA at a concentration of 500 ~g/ml at 37°(3 for 
an additional 3- and 22-h period. The supernates were lyophilized, assayed on SDS-polyacryl- 
amide gel electrophoresis (PAGE), and scanned at 550  nm. The aggregated gamma globulin 
was prepared by heating a  10-mg/ml solution of human gamma globulin to 65°C for 30 rain. 
Inhibitors.  The  inhibitory effects  of a  series  of enzyme  inhibitors including diisopropyl 
fluorophosphate (DFP) (Sigma Chemical Co., St. Louis, Mo.) at a 5  ×  10-4-M concentration, 
1-mg/ml  e-amino caproic acid  (EACA)  (Sigma Chemical  Co.),  N-a-p-tosyl-L-lysine  chloro- 
methyl ketone  (TLCK)  at  a  5  X  10-4-M concentration and  5  ×  10-4-M  h-l-tosylamide-2- 1022  DEGRADATION  OF  AMYLOID  A  BY  BLOOD  MONOCYTES 
FIG.  1.  Degradation of SAA and protein AA by peripheral blood monocytes. Slots 1 and 2 contain 
the initial medium solution with SAA and protein AA, respectively, before digestion with the cells. 
Slots 3, 5, and 7 are samples of SAA containing supernates incubated with cells for 2, 7, and 22 h, 
respectively, and slots 4, 6, and 8 are the AA protein containing supernates digested by the cells for 
2, 7, and 22 h, respectively (staining was done with Coomassie Blue). 
phenylethyl  chloromethyl  ketone (TPCK)  were also tested. 
Degradation of SAA  by  Glutaraldehyde Fixed Cells.  To inhibit  pinocytosis and  phagocytosis 
completely, monocytes were fixed with 0.1%-0.5% glutaraldehyde  in phosphate-buffered  saline 
(PBS) for 5 min at room temperature.  The fixed cells were then washed three times with PBS 
and incubated (1  ×  106 cells/tube)  with a 500-#g/ml solution of SAA in Dulbecco's medium. 
Cells incubated under identical  conditions  but not treated  with glutaraldehyde were used as 
controls. Samples of the medium were collected and assayed on gels for SAA content  after 5, 
24, and 48 h of incubation.  Samples of the glutaraldehyde-treated  cells were tested  for their 
ability to phagocytose by incubating them with latex particles for 30 min and examining them 
by electron microscopy (29, 30). 
Results 
Degradation of SAA  and  AA  by  Monocytes.  To  determine  whether  monocytes can 
degrade SAA and AA, cells obtained from the peripheral blood of 20 normal donors, 
3  of whom  were  studied  twice,  6  patients  with  primary  amyloidosis,  and  4  with 
secondary amyloidosis  were  isolated  and  tested  for  their  ability  to  degrade  these 
proteins  under the conditions described  in  Methods.  Fig.  1 shows the result  of one 
experiment  performed with  cells  from a  normal  donor. Both SAA and protein  AA 
were almost completely eliminated from the medium after incubation with the cells. 
Among the 30 individuals tested, three patterns of degradation of SAA were noted: 
(a)  a pattern in which SAA was completely degraded without the appearance of any 
intermediary  products on  the  acrylamide gels  (Figs.  1 and  2A).  This  degradation 
profile was found in eight normal individuals and none of the patients with amyloi- G.  LAVIE, D.  ZUCKER-FRANKLIN, AND E.  C.  FRANKLIN  1023 
FIG. 2.  Patterns  of degradation of SAA by macrophages: (A) Elimination of SAA after incubation 
with macrophages without the appearance of detectable degradation products on the gel. (B) 
Degradation of SAA by macrophages to a product comigrating with protein AA. Samples were 
collected after 24 h of incubation with the cells. (C) The cleavage  of SAA by maerophages  to an 
8,000 mol wt product which remains intact and is not further degraded. 
dosis;  (b)  a  pattern  in  which  the  12,500-dalton  SAA  molecule was  degraded  to  a 
product with a  tool wt of 7,000-9,000 daltons which comigrated on SDS-PAGE with 
protein AA isolated from amyloidotic tissues, and reacted with antibodies to protein 
AA in Ouchterlony double diffusion plates. This pattern of degradation (Fig. 2 B) was 
observed in cells of 8 normal individuals and all 10 patients with amyloidosis. Because 
this intermediate was degraded further with time, only a small portion of the protein 
could be found in this form when supernatant  samples were assayed between 2 and 
20 h  of incubation.  In most cases, the intermediate disappeared when the incubation 
period exceeded  24 h  (Fig.  2B);  (c)  In four instances, a  pattern of degradation was 
observed in which SAA yielded one or more degradation products having molecular 
weights  ranging between  7,000  and  9,000  dahons  which  remained even after incu- 
bations longer than 48 h  (Fig.  2 C).  The rate of elimination  of SAA by cells from a 
subject  that  degraded  SAA without  intermediates  (pattern  I)  was determined  in  a 
kinetic experiment in which SAA in concentrations ranging from 0.25 to 2.5  mg/ml 
was incubated with monocytes. Samples of the medium were collected after 1, 2, 3, 4, 
5, and  16 h. The results (Fig. 3) show that 30% of the protein is degraded by the cells 
during the first incubation hour when the initial concentration of SAA was 0.25 mg/ 
ml.  During  the initial  incubation  period, degradation  ranged  between  100  and  200 
#g/h per  106 cells depending on the SAA concentration. 
The frequencies of these three degradation patterns among normal cell donors and 
patients  with  amyloidosis  are  summarized  in  Table  I.  An  indication  that  these 
differences are not  technical  artifacts is  found  in  the  fact that  the patterns of SAA 
degradation for three individuals who were retested remained constant. 
Because  these  observations  suggested  that  the  SAA  degradation  pathway  by 
macrophages involves a  multistep reaction, with cleavage of the  12,500-dalton  SAA 
molecule to an intermediate product with  a  mol wt of 8,000  daltons, which  is  then 
followed by a  series of subsequent  steps which  eliminate  the  intermediate  AA-like 1024  DEGRADATION OF AMYLOID A BY BLOOD MONOCYTES 
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Fro.  3.  The kinetics of SAA degradation by monocytes. 10  ~ cells were incubted with 0.4 ml of 
Dulbecco's medium containing 2.5 (O), 1.5 (C)), and 0.25 mg/ml (A) of SAA. 0.05-ml Samples of 
the medium were collected after 1-5, and 16 h of incubation, assayed on SDS-PAGE  stained with 
Coomassie Blue and scanned. The results are expressed as percent SAA left in the medium after the 
incubation. 
TABLE  I 
Patterns of Degradation of SAA and AA by Monocytes  from Normal Donors and Patients with Amyloidosis 
Diagnosis 
Degradation of SAA 
8,000 Dalton intermediate 
Degradation of AA 
No  Degradation 
No  Complete Further degrada- No further deg- 
tion  radation 
Normal donors  20  8  8  4  18  16 
Primary amyloid  6  0  6  0  6  6 
Secondary amyloid  4  0  4  0  3  3 
product, we studied the handling by these cells of AA protein obtained from the liver 
of a  patient  with  secondary  amyloidosis after  treatment  of the  fibrils with  5  M 
guanidine. 
Fig,  1 shows that monocytes are also capable of degrading protein AA. The rate of 
elimination  of protein AA was similar to that of SAA. Though in general the handling 
of AA appeared similar for cells from normal subjects and patients with amyloidosis, 
cells from two of the normal donors which degraded  SAA to  a  stable 8,000 dalton 
component also failed to degrade protein AA, even when the incubation period was 
extended to 48 h. 
The Mechanisms of SAA Degradation by Macrophages.  Two mechanisms are primarily G.  LAVIE, D.  ZUCKER-FRANKLIN,  AND E.  C.  FRANKLIN 
TA~x.~ II 
Comparison of SAA Degradation by Monocytes and Monocyte Supernates Obtained Under 
Equivalent Conditions 
1025 
Amount of SAA  Amount of SAA 
left after 3-h in-  left after 20-h in- 
cubation  cubation 
#g  #g 
Incubation of 100/~g SAA with: 
Intact cells  10.3  2.9 
Supernates after 0.5-h incubation of cells with: 
Dulbecco's medium  92.5  76.4 
Dulbecco's medium +  aggregated y-globulin  89.4  84.0 
Dulbecco's medium +  latex particles  93.1  90.6 
Dulbecco's medium +  SAA*  87.7  78.3 
Supernates after 3-h incubation of cells with: 
Dulbecco's medium  90.7  87.3 
Dulbecco's medium +  aggregated y-globulin  89.1  82.6 
Dulbecco's medium +  latex particles  99.5  87.2 
Dulbecco's medium +  SAA*  88.9  80.0 
* Corrected for the amount of SAA added after the incubation with the cells. 
involved in the degradation  of proteins  and particulates  by macrophages  (22). The 
first  is  a  process  of endocytosis in  which  engulfment  of extracellular  material  into 
phagosomes or pinosomes is followed by fusion with  lysosomes and  degradation  by 
lysosomal enzymes. The second is through the release of active proteases by the cells 
into  the  extracellular  environment  where  degradation  of proteins  such  as  collagen 
(23),  elastin  (24),  and  plasminogen  (25),  is  believed  to  take  place.  Pinocytosis  or 
phagocytosis appeared unlikely because intracellular degradation is usually complete 
and  not  known to be associated with  the  discharge of partially  degraded  products. 
Therefore, we first examined the possibility that the cells secrete a proteolytic enzyme 
which cleaves the SAA molecule outside the cell. 
The degradation of SAA by 1 ×  106 intact monocytes was compared with that by 
supernates  obtained  from  the  same  cells  under  a  variety  of conditions.  Cells  were 
incubated  for  0.5  or  3  h  in  0.50  ml  of serum-free  Dulbecco's  medium,  the  same 
medium  with  100 #g/ml  aggregated  gamma  globulin,  latex  particles,  or with  low 
concentrations  of SAA (50 #g/ml).  The cells  were then spun  at  300 g, the  medium 
was collected,  and  incubated with  0.2  ml of SAA (500 #g/ml)  for 3  and  20 h  after 
which  the  supernates  were  lyophilized,  assayed  on  SDS-PAGE,  and  scanned  to 
determine  the amount of residual  SAA. The results presented  in Table II show that 
after 3 h of incubation, the intact cells were nine times more active than the supernates 
obtained  from cells  that  had  been  previously  incubated  for the  same  time  period, 
even  when  the  cells  had  been  exposed  to  aggregated  gamma  globulin  or  SAA. 
Differences in enzyme activity between tubes containing supernate or intact cells were 
even greater after a  20-h incubation period with SAA. Almost no SAA remained  in 
the  sample  incubated  with  intact  cells,  whereas  -~  80%  remained  in  the  samples 
exposed  to the culture supernates.  Because .these results  suggested  that  degradation 
takes place predominantly by cell-associated  enzymes and only to a  small extent  by 
enzymes released into the medium, experiments were designed to distinguish between 
cell surface as opposed to intracellular  degradation. 1026  DEGRADATION OF AMYLOID A BY  BLOOD MONOCYTES 
Fro.  4.  (1) Monocyte incubated with latex particles (L) before fixation. As was to be expected, 
numerous particles are  seen within  phagocytic vacuoles (arrows) (magnification ×7,000). (2) 
Monocyte fixed with 0.1% glutaraldehyde for 5 min before incubation with latex particles (L). 
Fixation completely inhibited interiorization of the particles (magnification × 7,000). 
TABLE III 
The Effect on Degradation of SAA and AA of Treatment of Monocytes with O. 1% 
Glutaratdehyde 
Time of incuba- 
tion 
SAA left after incubation with 
Protein AA left after incubation 
with 
Glut Aid* fixed  Glut Ald* fixed  Intact cells  Intact cells  cells  cells 
h  %  % 
5  37.4  69.9  59.1  42.9 
20  13.2  22.0  30.3  16.4 
48  --  --  12.4  8.9 
* Glut Aid, glutaraldehyde. 
Evidence of Enzymatic Activity Bound to the Cell Membrane and its Possible  Nature.  To test 
the  possibility that  the  enzymes may be associated with  the  outer part  of the  cell 
membrane, we treated the cells with 0.1%-0.5% glutaraldehyde in PBS for 5 min and 
assayed for the ability of these cells to degrade SAA and to interiorize latex particles. 
Whereas electron microscopy showed that  latex particle interiorization was entirely 
inhibited by 0.1%  glutaraldehyde (Fig. 4),  there was  no significant decrease in the 
amount of AA degraded (Table III) and only moderate inhibition  of SAA degradation 
after  5  h  of  incubation and  no  inhibition after  20  h.  The  mild  treatment  with 
glutaraldehyde did not appear to significantly affect the activity of the enzyme which 
could still degrade SAA and AA. Release of enzymes subsequent to glutaraldehyde 
fixation was excluded by showing that supernates obtained after 3  h  of incubation G.  LAVIE, D.  ZUCKER-FRANKLIN, AND E. C.  FRANKLIN 
TABLE IV 
The Effect of Enzyme Inhibitors on Degradation of SAA by Monocytes 
Inhibitor 
SAA degraded after 24-h  incubation of 
Cells  Cells  +  inhibitor 
% 
DFP, 5  ×  10  -4 M  88.0  1.2 
EACA, 100/~g/ml  18.3  21.9 
TLCK, 5  X  10  -4 M  86.8  91.1 
TPCK, 5  ×  10  -4 M  88.0  79.3 
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with SAA in a  manner similar to the studies in Table II did not degrade SAA (data 
not shown). This experiment provides additional support for the assumption that the 
enzymes which  degrade amyloid-related proteins are located  on  the surface of the 
cells.  Treatment  with  0.3  and  0.5%  glutaraldehyde  resulted  in  inactivation  of the 
enzyme. 
Table IV shows that  SAA degradation can be inhibited  by 5  ×  10  -4 M  DFP,  a 
concentration which was found not to impair cell viability or to inhibit interiorization 
of horse radish  peroxidase by the cells  (data not  presented).  TPCK, which  inhibits 
chymotrypsin-like activity, and TLCK, which inhibits trypsin-like activities, had no 
effect on this enzyme when tested at the same concentration.  This suggests that the 
enzyme  may  be  a  serine  esterase  not  related  to  trypsin-like  or  chymotrypsin-like 
enzymes. Soy bean trypsin inhibitor, pepstatin, leupeptin, antipain, and chymostatin 
had  no effect. The possibility that  the enzyme that  degrades AA is  a  plasminogen 
activator or a  complement component known to be elaborated by these cells seems 
unlikely  because  EACA,  which  inhibits  plasminogen-  and  complement-activator 
activities, had no effect either on SAA or on protein AA degradation  (Table IV). 
Discussion 
The structural  relationship of tissue protein AA to SAA has led to the belief that 
AA protein results from the cleavage of SAA, a  protein whose serum concentration 
rises and remains elevated for long periods of time during a  variety of inflammatory 
and other pathological states. Because proteolysis appears to play an important role 
in the genesis of all types of amyloid, it seems possible that phagocytic cells could play 
a role in the mechanisms of amyloid formation as well as removal. Such studies could 
perhaps also shed light on factors predisposing some individuals to develop the disease 
whereas others subjected to the same stimulus resist it. 
Our experimental  results suggest  that  monocytes are capable of degrading  SAA 
and AA through the action of one or more cell surface-associated enzymes rather than 
by interiorization or release of enzymes into the extracellular medium. In the case of 
SAA, the protein appears to be cleaved to an 8,000 dalton AA-like molecule and then 
further to smaller peptides.  The detection  of intermediate  degradation  products in 
some individuals and failure to find them in others may imply that there are multiple 
complex mechanisms involved in the degradation process of these two components. It 
seems possible that the two steps in the degradation of SAA involve separate enzymes 
or enzyme systems because unlike the majority of normal subjects and patients with 
amyloidosis  who  degrade  both  SAA  and  AA,  the  monocytes  from  four  normal 
individuals,  two  of whom  were  tested  twice,  were  found  to  be  deficient  in  the 1028  DEGRADATION OF AMYLOID A BY BLOOD MONOCYTES 
enzymatic activity responsible for the second stage. The cells of these donors degraded 
SAA to a persistent 8,000 mol wt product reactive with antisera to AA and also failed 
to degrade AA protein obtained from amyloidotic tissue. However, no other properties 
such as profiles of the effects of inhibitors or distribution of the enzymes on the cells 
could so far distinguish the enzymatic activities. If two separate enzymes are indeed 
involved, relatively larger amounts or higher rate of turnover of the second enzymatic 
system, which degrades the 8,000  dalton  intermediate and protein AA, may lead to 
the rapid elimination of these proteins and result in the first pattern of degradation. 
In  contrast,  a  slower  rate  of  degradation  of  AA  than  SAA  may  result  in  the 
accumulation of the intermediates yielding the second pattern of degradation.  Thus 
it is possible that the first two patterns of degradation which we classified as A and B 
simply reflect differences in the relative amounts of the two enzyme systems. Though 
it is not clear that the second enzymatic system is absent in cells of donors in whom 
the intermediate degradation products persist (type C), this possibility receives support 
from  the  finding  that  the  cells  of two  such  donors  failed  to  degrade  protein  AA 
derived from amyloidotic tissue. Because the in vitro assay system is not sufficient to 
permit any conclusions relating a defect in either step of processing to the pathogenesis 
of the disease, other types of experiments will be required to study that problem and 
to document the nature of the enzyme(s) involved. In addition,  the function of this 
degradative  system  in  the  processing  of other  proteins  remains  to  be  determined. 
Some  specificity  for  degrading  AA-related  proteins  is  suggested  by  the  failure  to 
observe a  similar rapid  degradation  by monocytes of other proteins  such  as Bence 
Jones proteins, ovalbumin, and serum albumin (G. Lavie, D. Zucker-Franklin, and E. 
C.  Franklin,  unpublished  observations), and  the  lack of inhibitory  effect of EACA 
which points away from an association of these proteolytic enzymes with complement 
activators or clotting factors. Similarly, though  it is not known whether the activity 
is  specific  for  monocytes  or  whether  it  is  associated  also  with  other  cell  types, 
preliminary data from studies currently in progress indicate that human lymphocytes 
isolated  from  peripheral  blood  as  described  elsewhere  (29)  are  also  capable  of 
degrading SAA, although perhaps less efficiently (unpublished observations). Mouse 
peritoneal macrophages also appear to possess similar enzymes on their surface. 
The mechanism by which the cells degrade the SAA and AA proteins is not a very 
common one. The almost complete preservation of the enzymatic activity after a brief 
treatment of the cells with glutaraldehyde together with the finding of extracellular 
intermediate breakdown products which disappear upon prolonged incubation, speak 
against a process of interiorization and intracellular digestion and point to a surface- 
associated enzyme. A  major role for proteolytic enzymes released by the cells after 
exposure  to  SAA  or  associated  with  phagocytosis  of latex  particles  or  aggregated 
gamma globulin appears unlikely because cell supernates were not nearly as effective 
as intact cells. Based on these positive results, and the inhibition of the process with 
DFP,  the  most  likely  mechanism  appears  to  involve  a  serine  protease  which  is 
predominantly associated with the cell membrane and is released by the cells only in 
minute  amounts.  Similar types of membrane-associated proteolytic activities,  have 
been observed in the brush border of kidneys (32)  on cytotoxic lymphocytes (33), on 
the membrane of mouse peritoneal macrophages which appear to contain an amino 
peptidase (34)  and on the surface of polymorphonuclear leukocytes (35), 
The possible relevance of the observed findings to the pathogenesis of amyloidosis G. LAVIE, D. ZUCKER-FRANKLIN, AND E. C. FRANKLIN  1029 
remains unanswered.  However, some of the differences in the behavior of cells from 
normal subjects and those with amyloidosis suggest a possible role in the pathogenesis 
of amyloidosis. Whereas 40% of normal cells degraded SAA without the appearance 
of any intermediates, all 10 patients with amyloidosis showed the transient appearance 
of a molecule with size and antigenic properties of AA, perhaps indicating a  quanti- 
tative  or  even  a  qualitative  deficiency  in  the  second  degradative  step.  During 
prolonged inflammation, when blood SAA levels are markedly increased, this type of 
degradation may result in the formation of large amounts of protein AA intermediates, 
the further degradation of which may be incomplete. The undegraded protein AA 
may find favorable conditions in the tissues to p01ymerize and form amyloid fibrils. 
The finding of a  similar pattern in  12 of the normal subjects, 4 of whom failed to 
degrade the intermediate further, may perhaps  identify individuals  predisposed to 
the development of amyloidosis once subjected to the inciting stimulus.  Studies of 
larger numbers of subjects,  family members, and  strains of mice differing in  their 
susceptibility to amyloidosis will be required to answer some of these questions. 
Summary 
Peripheral blood monocytes incubated in  a  serum-free medium  degraded serum 
amyloid A  (SAA) protein along three pathways. Of 20 normal subjects, 8 degraded 
SAA completely with no detectable intermediates. Eight subjects transiently produced 
an amyloid A  (AA)-like intermediate which comigrated on sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis (PAGE) with tissue AA protein and reacted with 
antisera  to AA, whereas  four subjects yielded a  persistent AA-like intermediate on 
PAGE. This group also failed to degrade tissue AA protein. Cells from  10 patients 
with amyloidosis fell into the second group. The responsible enzymes appear to be 
serine proteases because they are inhibited by diisopropyl fluorophosphate. They were 
not  affected  by  E-amino  caproic  acid,  L-l-tosylamide-2-phenylethyl chloromethyl 
ketone, or N-a-p-tosyl-L-lysine  chlormethyl ketone. It appears  possible that  the en- 
zymes are associated with the outer membrane of the cell because only a small fraction 
of the activity is secreted into the medium and because enzyme activity remains after 
fixation of the cells with glutaraldehyde which completely stops phagocytosis. Perhaps 
differences in patterns of proteolysis may play a role in the predisposition to amyloi- 
dosis. 
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